Cargando…

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% — an observational switch study

PURPOSE: The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of bimatoprost 0.01% solution in patients with primary open-angle glaucoma (POAG), who were switched from bimatoprost 0.03% solution, compared to patients with POAG who continued on bimatoprost 0.03% s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deshpande, Sarita S, Sonty, Sriram, Ahmad, Afzal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538690/ https://www.ncbi.nlm.nih.gov/pubmed/28794615 http://dx.doi.org/10.2147/OPTH.S137537

Ejemplares similares

Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension
por: Xu, Kai Man, et al.
Publicado: (2022)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
por: Chang-Lin, Joan-En, et al.
Publicado: (2011)

Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis
por: Carruthers, Jean, et al.
Publicado: (2016)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers, Jonathan S, et al.
Publicado: (2014)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Gheith, Moataz E, et al.
Publicado: (2008)

Efficacy of bimatoprost 0.03% in reducing intraocular pressure in patients with 360° synechial angle-closure glaucoma: A preliminary study
por: Vyas, Prateep, et al.
Publicado: (2011)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
por: Inoue, Kenji, et al.
Publicado: (2014)

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
por: Day, Douglas G, et al.
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura, Toyoaki, et al.
Publicado: (2012)

Comparative study of the efficacy and safety of topical minoxidil 2% versus topical bimatoprost 0.01% versus topical bimatoprost 0.03% in treatment of eyebrow hypotrichosis: a randomized controlled trial
por: Zaky, Mohamed S., et al.
Publicado: (2023)

Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China
por: Wang, Kaidi, et al.
Publicado: (2014)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
por: Pillunat, Lutz E, et al.
Publicado: (2016)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
Publicado: (2013)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
por: Goldberg, Ivan, et al.
Publicado: (2014)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee, Afshin, et al.
Publicado: (2013)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
por: Pfennigsdorf, Stefan, et al.
Publicado: (2016)

Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma
por: Mishra, Deepak, et al.
Publicado: (2014)

Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma
por: Filippelli, Mariaelena, et al.
Publicado: (2022)

In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: A patient-use study
por: Paolera, Mauricio D, et al.
Publicado: (2008)

Twenty-four-hour effects of bimatoprost 0.01% monotherapy on intraocular pressure and ocular perfusion pressure
por: Tung, Jonathan D, et al.
Publicado: (2012)

Cytotoxicity, Mitochondrial Functionality, and Redox Status of Human Conjunctival Cells after Short and Chronic Exposure to Preservative-Free Bimatoprost 0.03% and 0.01%: An In Vitro Comparative Study
por: Petricca, Sabrina, et al.
Publicado: (2022)

Topical Treatment of Eyebrow Hypotrichosis with Bimatoprost 0.03% Solution: Case Report and Literature Review
por: Riahi, Ryan R, et al.
Publicado: (2018)

Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension
por: Sun, Xinghuai, et al.
Publicado: (2022)

Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
por: Pfennigsdorf, Stefan, et al.
Publicado: (2012)

An observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial
por: Nixon, Donald R, et al.
Publicado: (2012)

Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting
por: Park, Ki Ho, et al.
Publicado: (2014)

Floppy eyelid syndrome and ectropion improvement after 1 month of 0.03% Bimatoprost topical therapy
por: De Gregorio, Alessandra, et al.
Publicado: (2020)

Late-day intraocular pressure–lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial
por: DuBiner, Harvey B, et al.
Publicado: (2014)

A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
por: Stevens, Annemie, et al.
Publicado: (2016)

A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension
por: Natt, Navreet Kaur, et al.
Publicado: (2014)

Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study
por: Chen, Ying Ying, et al.
Publicado: (2016)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober, Dietmar, et al.
Publicado: (2015)

An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan(®) RC Early Analysis Review (CLEAR) trial
por: Crichton, Andrew C, et al.
Publicado: (2014)

Dose–Response of Intracameral Bimatoprost Sustained-Release Implant and Topical Bimatoprost in Lowering Intraocular Pressure
por: Lee, Susan S., et al.
Publicado: (2019)

Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials
por: Wirta, David, et al.
Publicado: (2011)

A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost
por: Craven, E Randy, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_rktet0eqapgl6o577plfphbmtq